fda glp-1 warning november 2025 The growing availability of compounded weight-loss drugs has prompted warnings from doctors and the U.S. Food and Drug Administration. https://www.abc27.com/national/compounded-glp-1 -drugs-creating-concern-among-doctors-and-fda/?utm_medium Trends In FDA FY 2025

They serve as messengers in the body that tell your cells to perform certain functions

A qualified provider should evaluate your personal timeline expectations based on your medical history, baseline weight, metabolic markers, and prior medication responses

By improving cerebral blood flow, GLP-1s enhance glucose and oxygen delivery, support mitochondrial ATP production, and reduce energy insufficiency that promotes synaptic dysfunction, impaired protein clearance, and neuroinflammation [5]

Recent studies suggest that these compounds may influence the secretion of various gastrointestinal hormones, including glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK), and peptide YY (PYY), while simultaneously reducing ghrelin levels 1